MGCD265: Preliminary Phase I data

Preliminary data from an ongoing, open-label, dose-escalation, U.S. Phase I trial (Trial 101) in 10 evaluable patients showed that 24, 48, 96 and 150 mg/m 2 oral MGCD265 given daily for 21 days produc...